InsiderSignal.AI

InsiderSignal.ai

HALO - Halozyme Therapeutics, Inc.

Insider Sale by Torley Helen (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Torley Helen, serving as Pres, CEO at Halozyme Therapeutics, Inc. (HALO), sold 50,000 shares at $69.52 per share, for a total transaction value of $3,476,157.00. Following this transaction, Torley Helen now holds 767,780 shares of HALO.

This sale represents a 6.00% decrease in Torley Helen's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, March 2, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 4, 2026, 2 days after the trade was made.

Halozyme Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Torley Helen

Torley Helen

Pres, CEO

Helen I. Torley is the President and CEO of Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing innovative solutions like the Enhanze technology to enable subcutaneous drug delivery, reducing treatment burdens for patients.[[1]](https://www.wbcollaborative.org/women_leaders_ceo/helen-i-torley/)[[3]](https://www.youtube.com/watch?v=7KQ0wvMwWdc)[[6]](https://www.zoominfo.com/p/Helen-Torley/1176947403) She brings extensive experience in biotechnology commercialization, having led successful product launches including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®.[[1]](https://www.wbcollaborative.org/women_leaders_ceo/helen-i-torley/) Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer at Onyx Pharmaceuticals, where she oversaw the U.S. launch of Kyprolis and developed commercial capabilities in Europe, including collaborations with Bayer on Nexavar® and Stivarga®.[[1]](https://www.wbcollaborative.org/women_leaders_ceo/helen-i-torley/) Her career spans clinical development, medical affairs, and leadership roles, with a passion for improving patient outcomes in areas like multiple myeloma.[[3]](https://www.youtube.com/watch?v=7KQ0wvMwWdc) In 2018, she received the EY Entrepreneur of the Year® award in San Diego for Operational Excellence.[[1]](https://www.wbcollaborative.org/women_leaders_ceo/helen-i-torley/) Recently, as a corporate insider, she sold 59,850 shares of HALO stock for approximately $3.8 million in August 2025 under a pre-arranged plan, retaining 733,719 shares.[[4]](https://www.investing.com/news/insider-trading-news/halozymes-ceo-helen-torley-sells-38m-in-shares-93CH-4190491)

View full insider profile →

Trade Price

$69.52

Quantity

50,000

Total Value

$3,476,157.00

Shares Owned

767,780

Trade Date

Monday, March 2, 2026

3 days ago

SEC Filing Date

Wednesday, March 4, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Halozyme Therapeutics, Inc.

Company Overview

No company information available
View news mentioning HALO

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4499752

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime